Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
One of the key challenges in anticancer therapy is the toxicity and poor bioavailability of the anticancer drugs. Nanotechnology can play a pivotal role by delivering drugs in a targeted fashion to the malignant cells that will reduce the systemic toxicity of the anticancer drug. In this report, we show a stepwise development of a nanoparticle-based targeted delivery system for in vitro and in vivo therapeutic application in pancreatic cancer. In the first part of the study, we have shown the fabrication and characterization of the delivery system containing gold nanoparticle as a delivery vehicle, cetuximab as a targeting agent, and gemcitabine as an anticancer drug for in vitro application. Nanoconjugate was first characterized physico-chemically. In vitro targeting efficacy, tested against three pancreatic cancer cell lines (PANC-1, AsPC-1, and MIA Paca2) with variable epidermal growth factor receptor (EGFR) expression, showed that gold uptake correlated with EGFR expression. In the second part, we showed the in vivo therapeutic efficacy of the targeted delivery system. Administration of this targeted delivery system resulted in significant inhibition of pancreatic tumor cell proliferation in vitro and orthotopic pancreatic tumor growth in vivo. Tumor progression was monitored noninvasively by measuring bioluminescence of the implanted tumor cells. Pharmacokinetic experiments along with the quantitation of gold both in vitro and in vivo further confirmed that the inhibition of tumor growth was due to targeted delivery. This strategy could be used as a generalized approach for the treatment of a variety of cancers characterized by overexpression of EGFR.
Patra
Chitta Ranjan
CR
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
Bhattacharya
Resham
R
Wang
Enfeng
E
Katarya
Aaron
A
Lau
Julie S
JS
Dutta
Shamit
S
Muders
Michael
M
Wang
Shanfeng
S
Buhrow
Sarah A
SA
Safgren
Stephanie L
SL
Yaszemski
Michael J
MJ
Reid
Joel M
JM
Ames
Matthew M
MM
Mukherjee
Priyabrata
P
Mukhopadhyay
Debabrata
D
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D000068818:Cetuximab; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000379:methods*; D066246:ErbB Receptors / Q000096:biosynthesis / Q000276:immunology; D006046:Gold / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D053768:Metal Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D018796:Immunoconjugates; D003841:Deoxycytidine; D006046:Gold; D066246:ErbB Receptors; D000068818:Cetuximab; D000093542:Gemcitabine